Comments on the Medicare Drug Price Negotiation Program for IPAY 2027

Survivors for Solutions has submitted an official comment to the Centers for Medicare and Medicaid Services (CMS) regarding their draft guidance for the continuance of the IRA’s drug negotiation program through Initial Price Applicability Year 2027 (IPAY). At a glance, SFS is concerned about CMS charging ahead with implementing another round of price negotiations despite knowing the longer-term impacts of the first round of negotiations. Additionally, the comment provides feedback on how the agency can improve its listening sessions and enable patients to have a voice when discussing the Medicare Drug Price Negotiation Program.

See the official comment below.